PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...
Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...
ABILIFY Injection, an injectable form of ABILIFY for intramuscular use, provides healthcare professionals with the first ready-to-use single dose vial (9.75 mg/1.3 mL) of an atypical antipsychotic to ...
The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...
Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Control of ...
Otsuka Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Company announced today that the US FDA approved the supplemental New Drug Application for ABILIFY for the acute treatment of manic and mixed ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results